Full Answer
How much is a senseonics stock worth?
One share of SENS stock can currently be purchased for approximately $2.84. How much money does Senseonics make? Senseonics has a market capitalization of $1.27 billion and generates $4.95 million in revenue each year. The company earns $-175.17 million in net income (profit) each year or ($1.43) on an earnings per share basis.
What is senseonics'stock symbol?
What is Senseonics' stock symbol? Senseonics trades on the New York Stock Exchange (NYSE)AMERICAN under the ticker symbol "SENS." How do I buy shares of Senseonics?
Is senseonics P/E ratio good or bad?
The P/E ratio of Senseonics is -1.99, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. The P/E ratio of Senseonics is -1.99, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. Is Senseonics a buy right now?
What does senseonics holdings (sense) do?
Sign-up to receive the latest news and ratings for Senseonics and its competitors with MarketBeat's FREE daily newsletter. Senseonics Holdings, Inc. engages in the design, development, and commercialization of implantable continuous glucose monitoring system for people with diabetes.
What is happening with Senseonics?
Senseonics Holdings (SENS) Reports Q1 Loss, Tops Revenue Estimates. Senseonics (SENS) delivered earnings and revenue surprises of 0% and 16.15%, respectively, for the quarter ended March 2022.
Is Senseonics a good stock to buy?
Senseonics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.
Why did Senseonics drop?
Shares of Senseonics Holdings (SENS 1.98%) were sinking 14.3% as of 3:12 p.m. EDT on Thursday. The big drop came after the medical technology company announced the pricing of a public offering of its stock.
How high can Senseonics go?
The 3 analysts offering 12-month price forecasts for Senseonics Holdings Inc have a median target of 2.50, with a high estimate of 6.00 and a low estimate of 0.80. The median estimate represents a +143.90% increase from the last price of 1.02.
Is SENS FDA approved?
According to the company, with a 6-month sensor wear duration, Eversense E3 is the longest-lasting CGM device available for use in the U.S. Read: Announcing the FDA approval of Eversense E3 in February, Senseonics (SENS) projected $14M – $18M in global net revenue for this year.
What is the price target for NIO?
Stock Price TargetsHigh$447.97Median$202.02Low$147.06Average$218.74Current Price$21.72
Is Senseonics FDA approved?
Senseonics has won FDA approval for its six-month continuous glucose monitoring system. Yet, the long-awaited approval was overshadowed by 2022 revenue guidance that was around half of what analysts expected.
Who is buying Senseonics stock?
Top 10 Owners of Senseonics Holdings IncStockholderStakeShares bought / soldGeode Capital Management LLC1.45%-1,745Northern Trust Investments, Inc.(...0.87%-175,633Charles Schwab Investment Managem...0.65%+77,338Susquehanna Financial Group LLLP0.53%-2,116,4696 more rows
How many shares does Senseonics have?
Share StatisticsAvg Vol (3 month) 34.11MShares Outstanding 5463.26MImplied Shares Outstanding 6N/AFloat 8407.44M% Held by Insiders 18.56%7 more rows
Will Bionano Genomics stock go up?
Bionano Genomics Inc (NASDAQ:BNGO) The 3 analysts offering 12-month price forecasts for Bionano Genomics Inc have a median target of 8.00, with a high estimate of 12.00 and a low estimate of 6.00. The median estimate represents a +494.80% increase from the last price of 1.35.
When did FDA approve Sens?
The Eversense system first received FDA approval in 2018 to be used for up to 90 days. In August 2020, Senseonics announced its deal with Ascensia Diabetes Care to manage distribution of the Eversense products for several years along with an investment in the CGM maker.
Will solo stock go up?
Electrameccanica Vehicles Corp (NASDAQ:SOLO) The 2 analysts offering 12-month price forecasts for Electrameccanica Vehicles Corp have a median target of 10.75, with a high estimate of 14.00 and a low estimate of 7.50. The median estimate represents a +739.84% increase from the last price of 1.28.
Should I buy or sell Senseonics stock right now?
2 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Senseonics in the last year. There are currently 2 buy r...
What is Senseonics' stock price forecast for 2022?
2 Wall Street analysts have issued 12-month price objectives for Senseonics' stock. Their forecasts range from $4.00 to $6.00. On average, they pre...
How has Senseonics' stock performed in 2022?
Senseonics' stock was trading at $2.88 at the start of the year. Since then, SENS shares have decreased by 63.5% and is now trading at $1.05. View...
How were Senseonics' earnings last quarter?
Senseonics Holdings, Inc. (NYSEAMERICAN:SENS) announced its quarterly earnings data on Tuesday, May, 10th. The company reported ($0.03) earnings pe...
What guidance has Senseonics issued on next quarter's earnings?
Senseonics issued an update on its FY 2022 earnings guidance on Tuesday, June, 7th. The company provided earnings per share (EPS) guidance of for t...
Who are Senseonics' key executives?
Senseonics' management team includes the following people: Dr. Timothy T. Goodnow , Pres, CEO & Director (Age 60, Pay $1.07M) Dr. Mukul Jain ,...
Who are some of Senseonics' key competitors?
Some companies that are related to Senseonics include Mesa Laboratories (MLAB) , Hurco Companies (HURC) , Crawford United (CRAWA) , Sypris Solu...
What other stocks do shareholders of Senseonics own?
Based on aggregate information from My MarketBeat watchlists, some companies that other Senseonics investors own include VirnetX (VHC) , Advanced...
What is Senseonics' stock symbol?
Senseonics trades on the New York Stock Exchange (NYSE)AMERICAN under the ticker symbol "SENS."
How has Senseonics' stock price performed in 2022?
Senseonics' stock was trading at $2.68 at the beginning of the year. Since then, SENS shares have decreased by 60.8% and is now trading at $1.05....
How were Senseonics' earnings last quarter?
Senseonics Holdings, Inc. (NYSE:SENS) posted its quarterly earnings data on Tuesday, May, 10th. The company reported ($0.03) EPS for the quarter, h...
Who are Senseonics' key executives?
Senseonics' management team includes the following people: Dr. Timothy T. Goodnow , Pres, CEO & Director (Age 60, Pay $1.07M) Dr. Mukul Jain ,...
Who are some of Senseonics' key competitors?
Some companies that are related to Senseonics include Mesa Laboratories (MLAB) , Hurco Companies (HURC) , Crawford United (CRAWA) , Sypris Solu...
When did Senseonics IPO?
(SENS) raised $45 million in an IPO on Friday, March 18th 2016. The company issued 15,800,000 shares at $2.85 per share. Leerink Partners, Canaccor...
What is Senseonics' stock symbol?
Senseonics trades on the New York Stock Exchange (NYSE) under the ticker symbol "SENS."
How do I buy shares of Senseonics?
Shares of SENS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBul...
What is Senseonics' stock price today?
One share of SENS stock can currently be purchased for approximately $1.05.
How much money does Senseonics make?
Senseonics (NYSE:SENS) has a market capitalization of $486.42 million and generates $13.68 million in revenue each year. The company earns $-302.47...
About Senseonics
Senseonics Holdings, Inc. engages in the design, development, and commercialization of implantable continuous glucose monitoring system for people with diabetes. Its primary product is the brand Eversense, a gluscose monitoring device which includes sensor, smart transmitter, and mobile application.
Headlines
SENS: Is Senseonics Holdings a Smart Investment in 2022? - StockNews.com
Senseonics (NYSEAMERICAN:SENS) Frequently Asked Questions
5 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Senseonics in the last twelve months. There are currently 1 sell rating, 1 hold rating and 3 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" Senseonics stock.
What is the interest rate on Senseonics convertible notes?
The company succeeded and announced the terms of the deal on Friday morning: $50 million of convertible notes were sold with an interest rate of 5.25% .
How long does Senseonics continuous glucose monitor last?
Senseonics' continuous glucose monitoring system is called Eversense and it stands apart from other devices because it is implantable and can last for up to 90 days. While the device has not yet received FDA approval, Senseonics is already selling the device in Europe.
When will the notes mature?
The underwriters of the deal were granted a 30-day option to purchase an additional $7.5 million worth of notes. The notes mature on Feb. 1, 2023 , and can be converted into common stock at a price of $3.40 per share.
How much money does Senseonics generate?
There was some good news with Senseonics' announcement, though. The company will generate around $25 million in gross proceeds, most of which will go toward funding operations. Senseonics also announced the pricing of an offering of convertible senior notes due in 2025.
How much revenue does Senseonics have?
The company announced earlier this week that it expects second-quarter revenue between $4.4 million and $4.7 million. That's not enough to even come close to covering expenses.
NYSEMKT: SENS
You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More
What happened
Senseonics Holdings ( SENS -4.76% ), which makes continuous glucose monitoring systems for diabetes care, saw its shares rise 30.6% in August, according to data from S&P Global Market Intelligence. The stock started at $3.10 on Aug. 2, the first trading day of the month, and closed the month at $4.01.
So what
There wasn't a lot of news to explain the stock's surge last month. The company did report second-quarter earnings on Aug. 9 and there was some good news in the report. Senseonics reported revenue of $3.29 million, compared to only $260,000, year over year.
Now what
To be clear, this is a long-term play with a lot of risk, but that's not unusual for the biotech industry. Given the company already has gotten approval for its 90-day Eversense CGM and the growth expected for diabetes therapies, it's easy to see why investors see this as a risk worth taking.
Premium Investing Services
Invest better with the Motley Fool. Get stock recommendations, portfolio guidance, and more from the Motley Fool's premium services.
Who is Ian Bezek?
Ian Bezek has written more than 1,000 articles for InvestorPlace.com and Seeking Alpha. He also worked as a Junior Analyst for Kerrisdale Capital, a $300 million New York City-based hedge fund.
How much is Eversense worth in 2020?
Eversense is still in the early stages of commercialization. The company anticipates $12 million to $15 million in sales this year. That’s up dramatically from 2020 levels but is still rather modest in the grand scheme of things.
Is Ascensia Senseonics the only game in town?
However, Senseonics isn’t the only game in town. Other well-funded competitors like Abbott (NYSE: ABT) and Dexcom (NASDAQ: DXCM) are active in continuous glucose monitoring as well.
Is Eversense relaunched?
However, Ascensia was rebooting marketing efforts for Eversense in the United States. According to the company’s latest conference call, Ascensia has relaunched Eversense in the U.S. recently and hired several dozen marketing employees to get product sales rolling there.
Is Ascensia a Bayer company?
Ascensia is the offshoot of Bayer’s diabetes business and thus is a well-known global operation. Ascensia invested money in Senseonics and is distributing the Eversense line of products in many locales, particularly in Europe.
Does Senseonics have a cash balance?
It doesn’t guarantee success, but it does give the company a fighting chance. Senseonics also has a large cash balance; it held $178.6 million as of last quarter. This gives time for Ascensia to ramp up sales, and also for Senseonics to further its research and development to keep Eversense up to speed with rivals.
The SENS Stock Story
The Senseonics story is one of great promise, but not great results. The Dec. 2 market cap of $1.27 billion supports sales of $13.6 million over the last four quarters.
The Penny Stock Story
I have a basic prejudice against penny stocks. That is, if these ideas are so great, why haven’t venture capitalists jumped on it? Why does management need your money to reach the market?
The Bottom Line on SENS Stock
Senseonics is what I call a “good” penny stock. It’s working on a real product with serious potential. The company has been developing and refining its offering for many years, and the latest version shows promise.
